# Cortisol and insulin: mechanisms of visceral fat accumulation

- Canonical: https://nutrifit.health/knowledge/cortisol-insulin-synergy-visceral-fat-accumulation
- Language: en
- Published: 2026-10-08T19:50:32.077Z
- Updated: 2026-10-09T00:53:02.841Z
- Author: NutriFit Editorial

> 11β-HSD1, H6PD, lipid flux and tissue cortisol action: cellular, animal and human evidence, diagnostic limitations and why supplements do not establish a treatment protocol.

Cortisol and insulin coordinate the supply and storage of energy, even though many of their individual effects appear to oppose each other. Insulin supports storage after a meal and restrains fat mobilization. Glucocorticoids sustain glucose availability and can promote lipolysis, yet they also influence adipocyte differentiation and responsiveness to insulin. Chronic glucocorticoid excess can therefore accompany central fat accumulation and muscle loss. This does not mean that every expanding waist reflects excessive cortisol or that normal insulin secretion after eating is harmful.

Intracellular cortisol availability is regulated beyond the adrenal glands. The enzyme 11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1, can regenerate cortisol from cortisone within tissues. This is a prereceptor mechanism: circulating hormone concentration does not automatically equal the strength of its action in a particular cell. Genetic mouse models show that amplifying this process in adipose tissue can produce an adverse metabolic phenotype. Human studies are more heterogeneous, and inhibitor trials have not established a universal treatment for visceral obesity.

This article examines adrenal hormone production, 11β-HSD1/2, the endoplasmic reticulum, lipoprotein lipase, intracellular lipolysis, interactions between adipose tissue, liver and circulation, and the evidence on stress, sleep and interventions. It is a targeted scientific account with verification of key primary studies, rather than a systematic review or an individualized treatment plan.

## 1. From stress signalling to cortisol

### Hypothalamus, pituitary and adrenal cortex

Parvocellular neurons in the hypothalamic paraventricular nucleus release corticotropin-releasing hormone, CRH, and vasopressin, AVP, into the pituitary portal circulation. In anterior pituitary corticotrophs, CRH acts through CRHR1, predominantly engaging Gs, adenylyl cyclase, cAMP and PKA. AVP uses V1b receptors and the Gq–phospholipase C–IP3–calcium pathway. These signals interact in ACTH production and secretion. The precursor POMC is processed by enzymes including prohormone convertase PC1/3; ACTH then stimulates the adrenal gland.

In the zona fasciculata, ACTH binds MC2R. The accessory protein MRAP is necessary for normal receptor trafficking and function. Gs/PKA signalling acutely increases delivery of cholesterol to the inner mitochondrial membrane, involving StAR, and over longer periods modifies steroidogenic gene expression. Cortisol production depends on substrate supply, enzyme activity and cellular state as well as ACTH concentration.

Steroidogenesis is divided between mitochondria and the smooth endoplasmic reticulum, ER. Mitochondrial CYP11A1 converts cholesterol to pregnenolone by side-chain cleavage. One route to cortisol then uses CYP17A1, HSD3B2 and CYP21A2 in the ER, followed by mitochondrial CYP11B1 for the final 11β-hydroxylation:

$$
\begin{aligned}
\text{cholesterol}&\xrightarrow{\mathrm{CYP11A1}}\text{pregnenolone}\\
&\xrightarrow{\mathrm{CYP17A1}}\text{17-OH-pregnenolone}\\
&\xrightarrow{\mathrm{HSD3B2}}\text{17-OH-progesterone}\\
&\xrightarrow{\mathrm{CYP21A2}}\text{11-deoxycortisol}\\
&\xrightarrow{\mathrm{CYP11B1}}\text{cortisol}.
\end{aligned}
$$

This summarizes one sequence within a branching steroidogenic network. Tissue regeneration by 11β-HSD1 is different: it converts an existing cortisone molecule back to cortisol rather than synthesizing a new steroid from cholesterol.

### Rhythms, transport and feedback

The suprachiasmatic nucleus and peripheral molecular clocks coordinate daily activity of the hypothalamic–pituitary–adrenal axis. Cortisol usually rises toward the end of the biological night, reaches high levels in the morning and declines toward the biological evening. Ultradian pulses are superimposed on this circadian pattern. A normal profile is therefore not a smooth, continuously falling curve. The cortisol awakening response, CAR, is an additional change after awakening, not a synonym for the entire morning circadian maximum. Sleep, awakening time, shift work, illness and sampling conditions affect interpretation.

Most circulating cortisol is bound to corticosteroid-binding globulin, CBG, and albumin. The unbound fraction is small and dynamic. Fixed percentages are not universal because binding changes with protein concentrations, inflammation, estrogens, medication and CBG saturation. Total serum cortisol is consequently different from free cortisol or tissue action. Cortisol participates in negative feedback through the glucocorticoid receptor, GR, at the pituitary, hypothalamus and other brain structures.

## 2. Two enzymes with different jobs

11β-HSD1 and 11β-HSD2 are encoded by different genes and use different cofactors. They cannot be treated as a single therapeutic target: reducing cortisol regeneration in a metabolic tissue and impairing cortisol inactivation in the kidney can have fundamentally different consequences.

| Feature | 11β-HSD1 | 11β-HSD2 |
| :--- | :--- | :--- |
| Gene | HSD11B1 | HSD11B2 |
| Full-length human protein | 292 amino acids | 405 amino acids |
| Principal cofactor | NADPH for reduction; NADP+ for the reverse reaction | NAD+ for oxidation |
| Typical physiological reaction | Cortisone → cortisol in many intact metabolic cells | Cortisol → cortisone |
| Cellular topology | ER membrane anchor with catalytic domain in the lumen | Membrane-associated enzyme with catalytic portion facing the cytosolic side |
| Important tissues | Liver, adipose tissue, some brain and immune cells, other organs | Aldosterone-sensitive distal nephron, colonic epithelium, placenta and other tissues |
| Main consequence | Regulation of local access of active glucocorticoid to receptors | Protection of the mineralocorticoid receptor from cortisol in appropriate tissues |
| Loss of function | Impaired cortisol regeneration; rare inherited cortisone reductase deficiency | Apparent mineralocorticoid excess, AME |

“Typical” matters. Purified 11β-HSD1 can catalyse both directions; cofactor and substrate availability and metabolic coupling determine its direction in cells. 11β-HSD2 predominantly oxidizes cortisol physiologically, but this should not be described as an absolute thermodynamic irreversibility. Affinity and kinetic measurements depend on the assay. Comparing isolated Km values without their experimental conditions can be misleading.

### 11β-HSD2 protects the mineralocorticoid receptor

The mineralocorticoid receptor, MR, can bind both aldosterone and cortisol, while cortisol is much more abundant in blood. In aldosterone-sensitive renal cells, 11β-HSD2 limits cortisol access to MR by converting it to cortisone, which has substantially less receptor activity:

$$
\text{cortisol}+\mathrm{NAD}^{+}\xrightarrow{\mathrm{11\beta\!\text{-}HSD2}}\text{cortisone}+\mathrm{NADH}+\mathrm{H}^{+}.
$$

Selectivity is thus produced by tissue metabolism rather than an exclusively aldosterone-selective receptor. Classic experiments by Funder et al. (1988) and studies of AME support this concept. Severe inherited HSD11B2 defects permit excess cortisol-mediated MR signalling, potentially causing sodium retention, hypertension, potassium loss and metabolic alkalosis. Renin and aldosterone are usually suppressed in this phenotype. Presentation and severity vary; every defect does not produce an identical set of complications.

### 11β-HSD1 structure and reaction direction

11β-HSD1 belongs to the short-chain dehydrogenase/reductase, SDR, family. Its catalytic domain includes a Rossmann-like cofactor-binding architecture and a steroid-binding pocket. Ser170, Tyr183 and Lys187 contribute to catalytic organization. A residue’s structural role does not establish that a compound predicted to interact with it by docking will work as a medicine.

Structural records also require accurate interpretation. PDB 2IRW contains human 11β-HSD1 with NADP and an adamantane ether inhibitor; it was released in 2007 and is associated with Patel et al. PDB 4C7J is a modified human enzyme–inhibitor complex, not an apo structure. PDB 1Y5R represents murine 11β-HSD1 with corticosterone, not human 11β-HSD2. These structures inform active-site research but do not themselves establish visceral fat reduction in people.

## 3. The ER lumen: H6PD, NADPH and cortisol regeneration

An N-terminal segment anchors 11β-HSD1 in the ER membrane, while its catalytic domain faces the lumen. This is a separate redox compartment. Cytosolic glucose-6-phosphate dehydrogenase, G6PD, and luminal hexose-6-phosphate dehydrogenase, H6PD, are not interchangeable in an intact cell because the membrane restricts free exchange of pyridine nucleotides.

Glucose-6-phosphate, G6P, can enter through G6PT, encoded by SLC37A4. H6PD oxidizes G6P and reduces NADP+ to NADPH. H6PD also has lactonase activity and broader substrate specificity than a brief diagram conveys. NADPH supplies the reducing power for 11β-HSD1-mediated cortisone reduction. The two reactions must be distinguished:

$$
\begin{aligned}
\mathrm{G6P}+\mathrm{NADP}^{+}&\xrightarrow{\mathrm{H6PD}}\text{6-phosphogluconolactone}+\mathrm{NADPH}+\mathrm{H}^{+},\\
\text{cortisone}+\mathrm{NADPH}+\mathrm{H}^{+}&\xrightarrow{\mathrm{11\beta\!\text{-}HSD1}}\text{cortisol}+\mathrm{NADP}^{+}.
\end{aligned}
$$

H6PD does not convert cortisone to cortisol directly; it maintains cofactor availability for another enzyme. A high NADPH/NADP+ ratio favours reduction, but ratios such as 100:1 or 500:1 have not been established as universal adipocyte values. H6PD expression, G6P transport, metabolic state and cortisone availability can each constrain flux.

[![Luminal H6PD–11β-HSD1 cortisol regeneration versus cytosolic-facing renal 11β-HSD2 cortisol inactivation](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-cortisol-insulin-synergy-visceral-fat-accumulation-cortisol-er-shuttle-en-v1.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-cortisol-insulin-synergy-visceral-fat-accumulation-cortisol-er-shuttle-en-v1.png)

*Figure 1. The luminal G6PT–H6PD–11β-HSD1 system is separated from the cytosolic-facing action of 11β-HSD2. Arrows indicate reactions and cofactor availability, not measured rates or tissue concentration differences.*

Enzyme placement identifies the side facing the catalytic domain; membrane anchors and full protein topology are simplified. Panels represent different tissue contexts, not obligatory coexpression of both enzymes in an adipocyte.

Lavery et al. (2006) showed that H6PD-deficient mice lose normal regeneration of corticosterone from 11-dehydrocorticosterone and display increased reverse oxidation. These are murine glucocorticoids, not human cortisol and cortisone. The experiment supports the importance of luminal coupling; it does not show that greater dietary glucose inevitably increases cortisol regeneration in human visceral adipose tissue.

Rare human inactivating H6PD mutations also impair cortisol regeneration. Increased removal from the active hormone pool can provoke compensatory ACTH stimulation and adrenal androgen excess. Hirsutism, menstrual disturbance or other manifestations depend on age and sex (Lavery et al., 2008). H6PD-related deficiency is distinguished from defects in HSD11B1 itself. These are rare genetic conditions, not an explanation for every elevated ACTH value, acne presentation or polycystic ovary syndrome.

## 4. Visceral fat: human tissue evidence and mouse experiments

### Different depots and different measurements

Omental and mesenteric fat connect with the portal circulation. Retroperitoneal and perirenal depots also lie within the abdomen but do not have identical venous drainage or functions. Abdominal subcutaneous and gluteofemoral fat differ as well. A binary comparison of all visceral against all subcutaneous fat can therefore conceal substantial heterogeneity.

The “Cushing’s disease of the omentum” hypothesis introduced by Bujalska et al. (1997) is a metaphor for local cortisol regeneration, not an established diagnosis. Preadipocytes, mature adipocytes and the immune/stromal fraction differ biologically. Culture conditions can change enzyme expression and reaction direction. HSD11B1 mRNA, protein abundance, microsomal activity, reduction flux in intact tissue and directly measured tissue cortisol are distinct observations.

Human studies often associate increased adipose activity with obesity, including activity in subcutaneous tissue (Rask et al., 2002). A fixed several-fold visceral predominance and obligatory subcutaneous reduction are not general laws. Sex, obesity severity, diabetes, biopsy site, cellular composition and assay methodology affect results.

Podraza et al. (2024) provide useful counterevidence. Their human tissue study found lower expression of several cortisol-related genes in visceral fat with obesity, while direct measurements in paired specimens did not reveal corresponding tissue cortisol concentration differences. This does not invalidate local regeneration; it shows why one gene’s expression cannot be treated as a universal causal explanation or a measurement of hormone concentration.

Cytokines, C/EBP factors, glucocorticoid signalling and nutritional conditions can regulate HSD11B1 experimentally. Effects depend on cell type. The proposition that insulin always increases H6PD/G6PT and creates a continuous positive feedback loop in every human visceral adipocyte exceeds the evidence.

### Causality within a model and translation to humans

Masuzaki et al. (2001) generated mice overexpressing 11β-HSD1 under the adipose-associated aP2 promoter. Adipose corticosterone increased, visceral fat accumulation was accentuated by a high-fat diet, and glucose and lipid metabolism became abnormal. This demonstrates that amplifying local glucocorticoid action can be sufficient for the phenotype in that model. Promoter specificity and genetic background have limitations; the model does not determine what fraction of human obesity is caused by this process.

Hsd11b1 deficiency models attenuated some glucocorticoid-dependent responses and improved selected metabolic measurements (Kotelevtsev et al., 1997; Morton et al., 2001). Outcomes depend on strain, sex, diet and the tissue affected. They are not complete protection against every form of obesity. Changes in UCP1, PGC-1α or beige adipocyte features in particular models likewise do not establish that a supplement converts human visceral fat into thermogenic tissue.

## 5. Two lipid flows that must be kept separate

### Uptake from blood: LPL and GPIHBP1

Lipoprotein lipase, LPL, is synthesized by adipocytes and other cells, including myocytes. Maturation involves the ER/Golgi secretory pathway and accessory proteins such as LMF1. Secreted LPL must reach triglyceride-rich lipoproteins inside the capillary. Endothelial GPIHBP1 captures LPL on the tissue-facing side, transports it and holds it on the blood-facing surface (Beigneux et al., 2007). Its GPI anchor is in the endothelial cell membrane, not in the extracellular basement membrane.

Luminal LPL hydrolyses triglycerides in chylomicrons and VLDL, with necessary regulators including ApoC-II. Released fatty acids can enter adipocytes through pathways involving CD36 and FATP, bind FABP4, become acyl-CoA and enter lipid synthesis or oxidation. Some escape into the circulation. Uptake is neither complete nor exclusively visceral. Modern structural work shows that LPL can be catalytically active as a monomer; an obligatory active homodimer is an outdated simplification.

Fried et al. (1993) studied seven-day organ cultures of omental and subcutaneous tissue from people with obesity. Insulin alone increased LPL measurements in subcutaneous but not omental tissue. Dexamethasone enhanced LPL with depot- and sex-dependent responsiveness. Combined exposure produced synergy in both depots, and maximal activity in women could be greater subcutaneously. The study therefore supports hormonal interaction, not a universal five- to ten-fold increase confined to visceral fat.

Some changes involved gene expression and protein synthesis; others were posttranslational. The observation does not establish a particular arrangement of neighbouring GRE/SRE sites, obligatory GR/SREBP-1c co-binding or recruitment of p300/CBP and SWI/SNF at the human LPL promoter. Glucocorticoid and insulin pathways can coordinate an outcome at several levels.

### Mobilizing the intracellular lipid droplet

ATGL, HSL and monoglyceride lipase act on the cell’s own lipid stores rather than circulating lipoproteins. ATGL, encoded by PNPLA2, mainly initiates triglyceride hydrolysis; HSL, encoded by LIPE, is particularly important for diacylglycerol hydrolysis. cAMP/PKA stimulation alters phosphorylation of HSL and perilipin-1, PLIN1, while availability of ABHD5/CGI-58 regulates ATGL. Phosphorylation-site numbers depend on species and isoform; rodent residue numbers should not be assigned to human sequences without explanation.

Insulin binds its receptor tyrosine kinase and regulates metabolism through IRS, PI3K, PIP3 and Akt. PDE3B hydrolyses cAMP and is important for the antilipolytic response; reduced PKA activation limits stimulation of lipolysis. This network is more complex than a single mandatory Akt phosphorylation event, with additional regulators and context-dependent mechanisms.

Physiological suppression is substantial but incomplete. Basal turnover continues, and insulin resistance can impair suppression. An enlarged depot can therefore take up fatty acids while releasing them. A completely “closed exit” is inconsistent with ongoing turnover and cannot explain increased portal fatty acid delivery in obesity.

[![Capillary LPL fatty-acid uptake versus intracellular ATGL/HSL release, partial insulin antilipolysis and contextual cortisol action](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-cortisol-insulin-synergy-visceral-fat-accumulation-cortisol-insulin-lipid-flux-en-v1.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-cortisol-insulin-synergy-visceral-fat-accumulation-cortisol-insulin-lipid-flux-en-v1.png)

*Figure 2. Capillary LPL and intracellular lipases govern different flows. Insulin favours storage and reduces stimulated lipolysis; cortisol’s effects depend on dose, timing and cellular state. Arrow thickness is not quantitative, and depot growth depends on the balance of uptake, synthesis, mobilization and oxidation.*

### Esterification, new fatty acid synthesis and net balance

Esterification uses glycerol-3-phosphate and acyl-CoA. GPAT, AGPAT, phosphatidate phosphatases including lipin, and DGAT contribute to triglyceride synthesis. Insulin-responsive GLUT4-mediated glucose uptake can supply carbon and the glycerol backbone, alongside other sources including glyceroneogenesis. This differs from de novo lipogenesis, DNL, which creates new fatty acids from non-lipid precursors. Akt/mTORC1 and SREBP-1c can regulate ACLY, ACC, FASN and SCD1, but enzyme expression is not a measured metabolic flux.

Human cellular experiments demonstrate this distinction. Gathercole et al. (2011) observed decreased basal DNL after glucocorticoid exposure, while low-dose dexamethasone pretreatment enhanced insulin-stimulated lipogenesis. Inhibiting 11β-HSD1 removed cortisone’s effect in that system. These findings support contextual interaction, not an inevitable anabolic programme.

A qualitative accounting relationship is:

$$
\frac{dM_{\mathrm{TG}}}{dt}=J_{\mathrm{esterification}}-J_{\mathrm{hydrolysis}}.
$$

Here J_esterification is total formation of stored triglyceride and J_hydrolysis its total hydrolysis, in consistent mass-per-time units. Fatty-acid uptake, de novo lipogenesis and reesterification supply the formation flux. Oxidation of free fatty acids after hydrolysis changes their subsequent fate and is not subtracted from droplet mass a second time.

M denotes stored triglyceride mass, t time, and J consistently defined mass-per-time flows. This is an accounting illustration, not a clinical equation for visceral fat. Reesterification and lipolysis must be defined consistently to avoid counting an internal cycle twice. Hormones alter substrate allocation, flux and appetite; they do not remove the requirement for energy balance.

## 6. Receptors, muscle and fat distribution

GR, encoded by NR3C1, contains an N-terminal transactivation region, a zinc-finger DNA-binding domain, a hinge and a C-terminal ligand-binding domain. Function depends on Hsp90/Hsp70 chaperone machinery, cochaperones, FKBP51/FKBP52, receptor modifications and chromatin accessibility. Ligand binding changes receptor conformation and nuclear trafficking, but simultaneous complete release of every chaperone is not an obligatory universal step. GR regulates transcription through glucocorticoid response elements and interactions with other factors. A canonical GRE sequence does not establish a functional response site in any particular promoter.

Some studies identify depot differences in receptor abundance or sensitivity. A constant three- to five-fold visceral predominance across all people has not been established. Cell type, sex hormones, differentiation, isoforms and steroid metabolism matter. Higher ligand exposure does not necessarily yield a proportionally greater response because adaptation and receptor sensitivity can change.

Prolonged marked glucocorticoid exposure in skeletal muscle can reduce protein synthesis and activate degradation pathways. FoxO factors and the E3 ubiquitin ligases MuRF1/TRIM63 and atrogin-1/FBXO32 participate in experimental atrophy mechanisms. Altered insulin signalling, glucose transport and mTOR-related processes can contribute. Nevertheless, a large waist with low muscle mass is not specific to cortisol: ageing, inactivity, inadequate nutrition, illnesses and medication may produce similar findings.

Central fat redistribution and muscle weakness are clinically important in Cushing syndrome and prolonged pharmacological glucocorticoid excess. Transferring the entire syndrome to common obesity without evidence of hypercortisolism is inappropriate. Functional subcutaneous storage may protect against ectopic lipid deposition; differences at the same BMI are explored in [TOFI and ectopic fat](/knowledge/tofi-phenotype-ectopic-fat-visceral-adiposity).

## 7. From adipocyte enlargement to metabolic complications

### Inflammation, adiponectin and PAI-1

Adipose expansion can accompany insufficient vascular support, hypoxia, extracellular matrix remodelling and cell death. Macrophages surrounding dead adipocytes form crown-like structures. IL-6, CCL2/MCP-1 and other mediators participate in interactions among immune, stromal and adipose cells; immune cells are an important source of TNF. An M1/M2 distinction is a useful introductory shorthand but does not encompass human tissue macrophage diversity.

Adiponectin signalling through AdipoR1/2 is associated with AMPK pathways, lipid oxidation and insulin sensitivity. Circulating levels are often lower in metabolically adverse obesity. However, obligatory direct suppression of ADIPOQ and PPARγ by cortisol with a uniform two- to four-fold fall in adiponectin has not been established. Glucocorticoids are also used to induce adipogenesis in culture. Their anti-inflammatory, metabolic and immune effects depend on time, dose and cell type; local regeneration does not automatically create a “cytokine storm.”

PAI-1, encoded by SERPINE1, limits fibrinolysis and is associated with metabolic abnormalities. Glucocorticoids can affect its expression experimentally, but circulating PAI-1 has multiple sources, including adipose tissue, liver, endothelium and platelets. Cardiovascular and thrombotic risk cannot be attributed entirely to one adipose enzyme. Clinical risk is determined by interacting factors rather than presumed activation of one pathway.

### The portal hypothesis and hepatic metabolism

Omental and mesenteric venous drainage can deliver lipids and mediators directly to the portal system. This provides a rationale for the portal hypothesis, but does not establish visceral tissue as the only or predominant source of every fatty acid entering the liver.

Nielsen et al. (2004) combined isotope methods and hepatic vein catheterization in humans with varying adiposity. The contribution of splanchnic lipolysis to hepatic fatty acid delivery ranged from less than 10% to almost 50% and increased with visceral fat. This is more accurate than asserting that portal concentrations are universally three to five times systemic concentrations. Subcutaneous tissue also contributes substantially to systemic fatty acid flux and hepatic delivery.

Excess substrate delivery can increase hepatic triglyceride stores and signalling lipids. A diacylglycerol–PKCε mechanism can impair insulin receptor function. Petersen et al. (2016) identified human receptor Thr1160 as a PKCε target in biochemical experiments; mutation of homologous murine Thr1150 protected against some high-fat diet effects. This is an important causal experiment, not proof of the sole mechanism of human insulin resistance. Lipid species and subcellular location matter. Ceramides affect additional pathways rather than automatically acting through the same reaction.

Failure to suppress hepatic glucose production can coexist with continued lipid synthesis. “Selective insulin resistance” describes this apparent paradox, but lipogenesis also depends on carbohydrate and fatty acid supply, hyperinsulinaemia and other signals. All hepatocytes should not be represented as having one pathway completely switched off while another remains uniformly intact.

The liver clears a substantial and variable fraction of insulin during first passage. Clearance involves receptor binding, endocytosis, intracellular degradation and other regulators; IDE is not its sole determinant. Reduced clearance with steatosis and metabolic dysfunction can amplify hyperinsulinaemia, but direction of causality and pancreatic compensation vary. Fasting indices describe a systemic phenotype without measuring local cortisol regeneration; see [HOMA-IR, TyG and QUICKI](/knowledge/homa-ir-tyg-index-quicki-insulin-resistance-markers).

### RAAS, kidney and blood pressure

Adipose tissue expresses renin–angiotensin system components including angiotensinogen and interacts with vascular and renal regulation. In a separate experiment, Masuzaki et al. (2003) found hypertension, salt sensitivity and altered circulating RAAS in mice with adipose 11β-HSD1 amplification; AT1 blockade abolished hypertension in that model. This is separate from the 2001 report and does not establish the same leading cause of hypertension in humans.

Human obesity-related hypertension involves sympathetic activity, sodium handling, sleep apnoea, vascular changes, RAAS and other influences. Perirenal and renal sinus fat may affect local mechanics and blood flow, but expansion does not inevitably imply compression, increased renin or refractory renovascular hypertension. Aldosterone-mediated RAAS effects must also be distinguished from cortisol-mediated MR activation when 11β-HSD2 is inhibited.

## 8. Sleep, biological rhythms and stress-related eating

Chronic stress may alter cortisol’s daily slope or awakening response, but individuals differ. Stress does not invariably mean persistent hypercortisolaemia: increased or blunted reactivity and altered timing are possible. A flattened profile is an association or research phenotype, not a specific diagnosis of the cause of obesity.

Insufficient sleep, shift work and social jet lag can impair glucose regulation and change eating behaviour. Sleep and HPA regulation interact bidirectionally. Insomnia should not be reduced to cortisol directly blocking one neuronal population, nor should a uniform 60–80% reduction in nocturnal growth hormone be assumed. Growth hormone pulses depend on sleep architecture, age, sex and metabolism; the physiological signal is not a separate programme of “nocturnal visceral fat burning.”

Spiegel et al. (2004) investigated short-term sleep restriction in 12 healthy young men and identified changes in leptin, ghrelin and appetite. Laboratory sleep and feeding conditions limit translation to every person with chronic insomnia. Lower leptin after short-term restriction and high leptin with obesity occur in different contexts rather than forming a universal sequence.

Dallman et al.’s (2003) comfort food model primarily interprets rodent experiments: palatable energy-dense food, fat stores and glucocorticoids can modify chronic stress responses. Human stress may increase or decrease eating. Reward circuitry, learning, food availability and social conditions matter, but a mandatory sequence of sugar, serotonin, CRH shutdown and instant storage of all energy in the omentum is unproven. Sustained overeating can expand fat stores; brief subjective relief does not make food a treatment for stress.

## 9. 11β-HSD1 inhibitors: testing the hypothesis clinically

Selective small molecules were developed to limit active glucocorticoid regeneration. Compounds studied include INCB13739, MK-0916, AZD4017 and others. Results vary by tissue, disease and trial. A list of investigational compounds is not a list of recommended medicines for waist reduction.

Rosenstock et al. (2010) randomized 302 people with type 2 diabetes inadequately controlled by metformin to one of five INCB13739 doses or placebo for 12 weeks. At 200 mg daily, placebo-adjusted HbA1c decreased by approximately 0.6 percentage points, fasting glucose by 24 mg/dL and HOMA-IR by approximately 24%. Lipid improvements were particularly apparent in hyperlipidaemic subgroups, and weight decreased modestly. These are results in a defined population, not an individual dosing recommendation.

| Outcome assessed | Appropriate interpretation | What it does not establish |
| :--- | :--- | :--- |
| HbA1c over 12 weeks | Short-term effect alongside metformin | Prevention of complications or universal obesity treatment |
| Fasting glucose and HOMA-IR | Improvement in surrogate measurements | Clamp-measured improvement specifically in hepatic insulin sensitivity |
| Lipids and body weight | Some favourable changes | Demonstrated reduction in quantitatively measured visceral fat |
| ACTH and androgens | Compensatory endocrine changes require observation | Obligatory hirsutism, alopecia or adrenal hyperplasia |

ACTH rose reversibly and dose-dependently, generally within reference limits. Basal cortisol homeostasis was maintained, and the female free androgen index was unchanged. The trial therefore does not support claiming demonstrated clinical hyperandrogenism in its female participants. Compensatory axis activation and changes in steroid precursors remain relevant to long-term safety.

A single “adrenal rebound” mechanism cannot explain every development programme’s limitations. Effect size, tissue exposure, sustained target engagement, disease selection and safety matter. The study associated with 4C7J also described absence of weight, glucose or insulin changes in particular high-fat diet mouse models despite strong target engagement (Goldberg et al., 2014). An attractive molecular target does not guarantee that every inhibitor will be clinically effective.

## 10. Polyphenols: an enzyme experiment is not a treatment

### EGCG

Hintzpeter et al. (2014) studied human hepatic microsomes and purified 11β-HSD1. EGCG inhibited reduction with an IC50 of approximately 57.99 μmol/L; the oxidation value was approximately 131.2 μmol/L. Kinetics supported competition with substrate and/or cofactor, while docking suggested an interaction with Lys187. IC50 is the concentration producing half-maximal inhibition in that assay, not a human dose or proof that free EGCG reaches that concentration in the adipocyte ER lumen.

Absorption, metabolites, protein binding and liver–adipose differences complicate translation. Improvement in a clinical measurement after a tea extract also does not establish 11β-HSD1 as the mechanism. A universal recommendation of 400–800 mg pure EGCG daily to treat local hypercortisolism is unsupported. EFSA (2018) associated concentrated supplement exposure at 800 mg/day or above with increased transaminases; a reliable safe supplemental threshold below that amount was not established. Ordinary tea infusion differs from a concentrated product.

### Curcumin and resveratrol

Hu et al. (2013) observed curcumin inhibition of 11β-HSD1 in cellular systems with human and rat enzymes. Effects on 11β-HSD2 occurred at higher concentrations as well. A rat experiment used 200 mg/kg for two months and assessed metabolic outcomes. This is not a human dose or proof that curcumin switches off HSD11B1 epigenetically in people. NF-κB, C/EBP and AMPK may participate in experimental polyphenol effects, but broad mechanistic lists do not replace clinical endpoint measurement.

Resveratrol inhibited 11β-HSD1 in rat adipose microsomes and 3T3-L1 cells (Tagawa et al., 2013), not human adipose explants. SIRT1/PGC-1α and thermogenesis are separate research questions. Universal direct SIRT1 activation and transformation of human visceral depots do not follow from the enzyme experiment. The publication has a 2014 correction; interpretation requires its current version, and unverified specific numerical claims should be avoided.

The full text of the 2014 erratum could not be obtained during preparation; its specific correction was not verified, and dependent numerical or figure details are not used to support clinical conclusions.

| Compound | Mechanistic experimental system | Main limitation |
| :--- | :--- | :--- |
| EGCG | Human hepatic microsomes and purified enzyme | No established therapeutic suppression of adipose 11β-HSD1 after ordinary intake |
| Curcumin | Cellular enzyme assays and a high-dose rat model | Cannot be translated directly to human visceral fat or dosing |
| Resveratrol | Rat microsomes and a murine cell line | No established clinical benefit mediated through this target in people |

Piperine-containing, micellar and phospholipid formulations may change bioavailability, but higher exposure does not equal improved clinical outcomes. Piperine may also alter medication metabolism. A “2000%” figure from a particular pharmacokinetic experiment does not mean that glucuronidation is suppressed by that amount in every person.

## 11. Licorice and 11β-HSD2: a different target and risk

Licorice glycyrrhizin and its metabolites, including glycyrrhetinic acid, can alter cortisol metabolism, including inhibition of renal 11β-HSD2. They cannot be considered a safe substitute for selective 11β-HSD1 inhibition. IC50 varies with compound form, enzyme preparation and conditions; a single nanomolar number does not determine safe consumption.

When cortisol is insufficiently inactivated, distal nephron MR signalling increases sodium transport, including ENaC-related pathways, and promotes potassium loss. Hypertension, oedema, hypokalaemia and alkalosis may develop. Severe potassium depletion can cause muscle weakness and dangerous arrhythmias. Unlike primary hyperaldosteronism, renin and aldosterone are usually low, hence the terms acquired apparent mineralocorticoid excess or pseudohyperaldosteronism.

Human observations by Stewart et al. (1987) support this mechanism. Af Geijerstam et al. (2024) studied 28 healthy young participants in a nonblinded randomized crossover trial. Two weeks of licorice containing 100 mg glycyrrhizic acid daily increased home systolic pressure and suppressed renin and aldosterone. The tested exposure is not a safe limit. Amount, duration and individual susceptibility affect response.

People with hypertension, cardiac or renal disease, or medication affecting potassium particularly need to identify licorice in teas, sweets and supplements. Palpitations, marked weakness or worsening blood pressure during use warrant clinical assessment. Deglycyrrhizinated licorice, DGL, contains less glycyrrhizin, but residual content, labelling and product quality vary; this does not automatically establish safety or efficacy for another indication.

## 12. Stress supplements and practical interventions

Small ashwagandha trials assess perceived stress, sleep and serum cortisol. Chandrasekhar et al. (2012) randomized 64 adults with chronic stress for 60 days. An approximately 27.9% cortisol reduction describes change within the extract group, not the same percentage difference from placebo. Adipose 11β-HSD1 and visceral fat were not measured. Root extracts and root/leaf mixtures differ; one product’s results do not apply automatically to all preparations.

NCCIH notes limited long-term evidence, gastrointestinal effects, drowsiness and rare liver injury. Ashwagandha is avoided in pregnancy; thyroid disease, autoimmune conditions and medication interactions matter. Lowering one cortisol measurement is not itself an indication for supplementation or evidence of improved function across the HPA axis.

Hellhammer et al. (2004) studied a phosphatidylserine/phosphatidic acid complex, PAS, in 80 participants. After three weeks, 400 mg of the complex blunted hormonal responses to a standardized stress test, whereas higher doses did not show the same effect. This is not a universal dose-dependent effect of pure phosphatidylserine or evidence of restored CAR or reduced visceral fat. Small exercise and emotional-response trials likewise measure their specific endpoints.

Magnesium is physiologically important, and correction of insufficient intake can be appropriate. A universal evening “anti-cortisol” regimen is not established. Salt form, elemental amount, dietary supply, gastrointestinal effects, kidney function and interactions matter. Small L-theanine studies address selected stress or cognitive measurements without establishing treatment of local hypercortisolism. These approaches do not replace investigation of symptoms.

### Diet and meal timing

Sustained reduction of excess weight requires consideration of overall intake, activity, environment and, when indicated, clinical treatment. Whole foods, fibre, adequate protein and reducing repeated excess intake of energy-dense food can help. Normal insulin secretion after a mixed meal is necessary; eliminating it is not a treatment goal. Carbohydrate does not inevitably cause visceral obesity because physiological cortisol is present.

Sutton et al. (2018) examined early time-restricted eating in a small controlled crossover study of men with prediabetes. A six-hour window ending before 3 pm was compared with a twelve-hour schedule while weight was maintained. Some insulin sensitivity measurements improved. This supports investigation of timing, not a universal requirement for eating only from 8 am to 4 pm, avoiding all evening meals or suppressing 11β-HSD1. Diabetes medication, pregnancy, undernutrition risk and eating disorders require individualized decisions.

### Sleep, light and exercise

Regular sleeping and waking times, suitable daytime light and limiting excessive evening illumination can support alignment with biological rhythms. Light effects depend on timing, duration, spectrum and individual phase; 10,000 lux immediately after awakening does not guarantee CAR normalization. A comfortable bedroom temperature can help sleep, but 17–19 °C is not a mandatory treatment for altered cortisol. Loud snoring, breathing pauses or daytime sleepiness warrant assessment for sleep apnoea.

Aerobic and resistance exercise support metabolic health and muscle preservation. Intensity is adapted to health and recovery. “Zone 2” does not have one fixed correspondence to lactate of 1.5–2.0 mmol/L or a universal percentage of maximal heart rate. Transient exercise-related cortisol elevation is part of normal adaptation, not evidence that HIIT damages the adrenal glands. “Adrenal fatigue” in this everyday sense is not an established diagnosis.

## 13. What can be evaluated clinically?

Waist circumference, blood pressure, lipids, glycaemia, medication history, sleep and muscle function help characterize risk. Waist thresholds vary by sex, population and guidance; they do not measure local 11β-HSD1 activity. Imaging can characterize visceral and ectopic fat when appropriate, but also does not establish a hormonal cause.

Cushing syndrome describes chronic pathological glucocorticoid excess; Cushing disease is its pituitary ACTH-dependent form. A normal morning cortisol does not exclude the syndrome, and an isolated high value does not confirm it. Endocrine Society guidance recommends selecting late-night salivary cortisol, urinary free cortisol or dexamethasone suppression testing when sufficiently suggestive or progressive clinical features warrant evaluation, with appropriate sampling and repetitions. Widespread screening of everyone with obesity or random cortisol/ACTH measurement is not recommended as a detection strategy.

The urinary metabolite ratio (THF + allo-THF)/THE is used in steroid metabolism research but depends on more than 11β-HSD1: 11β-HSD2, 5α/5β reduction and other processes contribute. It is not an assay of omental enzyme activity alone. Steroid reduction and phase II conjugation are also different metabolic steps.

## 14. Common questions

### Can normal blood cortisol coexist with altered tissue action?

Yes. Local regeneration, receptors, binding proteins and cellular context affect exposure and response. This possibility does not establish local hypercortisolism in every person with an enlarged waist.

### How can cortisol mobilize fat yet accompany central obesity?

It acts across tissues and timescales. Lipolysis, uptake, differentiation, insulin interaction, intake and expenditure can change together. The outcome reflects net flux rather than one hormone action.

### Can an enzyme-inhibiting supplement reduce visceral fat?

An assay does not establish tissue exposure, selectivity or clinical benefit. EGCG, curcumin and resveratrol do not have a universally validated regimen for treating visceral obesity through 11β-HSD1.

### Why does licorice require particular attention?

It can impair renal cortisol inactivation through 11β-HSD2 and increase MR signalling. Hypertension and potassium loss are clinical risks, not a safe method of regulating tissue cortisol.

### Should everyone measure cortisol and avoid insulin responses?

No. Cortisol testing is selected according to clinical findings and conditions, and physiological insulin responses are necessary. Metabolic health requires a broader assessment and practical choices fitted to individual needs.

Tissue glucocorticoid regeneration explains part of hormonal fat regulation. The strongest conclusions concern enzymatic reactions, cellular compartments and defined experimental models. Human obesity requires attention to heterogeneous tissues and findings, energy balance, clinical context and the absence of a universal treatment inferred from one molecular pathway.

## FAQ

### Can normal blood cortisol coexist with altered tissue action?

Yes. Local regeneration, receptors, binding proteins and cellular context affect exposure and response. This possibility does not establish local hypercortisolism in every person with an enlarged waist.

### How can cortisol mobilize fat yet accompany central obesity?

It acts across tissues and timescales. Lipolysis, uptake, differentiation, insulin interaction, intake and expenditure can change together. The outcome reflects net flux rather than one hormone action.

### Can an enzyme-inhibiting supplement reduce visceral fat?

An assay does not establish tissue exposure, selectivity or clinical benefit. EGCG, curcumin and resveratrol do not have a universally validated regimen for treating visceral obesity through 11β-HSD1.

### Why does licorice require particular attention?

It can impair renal cortisol inactivation through 11β-HSD2 and increase MR signalling. Hypertension and potassium loss are clinical risks, not a safe method of regulating tissue cortisol.

### Should everyone measure cortisol and avoid insulin responses?

No. Cortisol testing is selected according to clinical findings and conditions, and physiological insulin responses are necessary. Metabolic health requires a broader assessment and practical choices fitted to individual needs.

## Sources

- [Bujalska et al. (1997). Does central obesity reflect Cushing’s disease of the omentum?](https://pubmed.ncbi.nlm.nih.gov/9130942/)
- [Masuzaki et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome.](https://pubmed.ncbi.nlm.nih.gov/11739957/)
- [Kotelevtsev et al. (1997). 11β-HSD1 knockout mice: glucocorticoid responses and hyperglycemia.](https://pmc.ncbi.nlm.nih.gov/articles/PMC25139/)
- [Morton et al. (2001). Improved lipid and glucose profiles in large adipocytes of 11β-HSD1 knockout mice.](https://doi.org/10.2337/diabetes.50.9.2095)
- [Fried et al. (1993). Lipoprotein lipase regulation by insulin and glucocorticoid in human adipose depots.](https://www.jci.org/articles/view/116821)
- [Rask et al. (2002). Tissue-specific changes in peripheral cortisol metabolism in obese women.](https://pubmed.ncbi.nlm.nih.gov/12107245/)
- [Gathercole et al. (2011). Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue.](https://pubmed.ncbi.nlm.nih.gov/22022575/)
- [Podraza et al. (2024). microRNA, cortisol metabolism and human adipose tissue in obesity.](https://www.mdpi.com/1422-0067/25/10/5058)
- [Lavery et al. (2006). H6PD knockout mice lack 11β-HSD1-mediated glucocorticoid generation.](https://pubmed.ncbi.nlm.nih.gov/16356929/)
- [Lavery et al. (2008). Inactivating H6PD mutations in patients with cortisone reductase deficiency.](https://pubmed.ncbi.nlm.nih.gov/18628520/)
- [Funder et al. (1988). Mineralocorticoid action: target tissue specificity is enzyme mediated.](https://pubmed.ncbi.nlm.nih.gov/2845584/)
- [RCSB PDB 2IRW (released 2007). Human HSD1 with NADP and adamantane ether inhibitor; Patel et al.](https://www.rcsb.org/structure/2IRW)
- [RCSB PDB 4C7J (released 2014). Human HSD1 inhibitor complex; Goldberg et al.](https://www.rcsb.org/structure/4C7J)
- [RCSB PDB 1Y5R. Murine 11β-HSD1 complexed with corticosterone.](https://www.rcsb.org/structure/1Y5R)
- [Beigneux et al. (2007). GPIHBP1 and lipolytic processing of chylomicrons.](https://doi.org/10.1016/j.cmet.2007.02.002)
- [Birrane et al. (2019). Structure of the LPL–GPIHBP1 complex mediating plasma triglyceride hydrolysis.](https://pubmed.ncbi.nlm.nih.gov/30559189/)
- [Nielsen et al. (2004). Splanchnic lipolysis in human obesity.](https://www.jci.org/articles/view/21047)
- [Petersen et al. (2016). Insulin receptor Thr1160 phosphorylation and hepatic insulin resistance.](https://pubmed.ncbi.nlm.nih.gov/27760050/)
- [Masuzaki et al. (2003). Adipose glucocorticoid amplification causes high blood pressure in mice.](https://pmc.ncbi.nlm.nih.gov/articles/PMC162290/)
- [Dallman et al. (2003). Chronic stress and obesity: a new view of comfort food.](https://pmc.ncbi.nlm.nih.gov/articles/PMC208820/)
- [Spiegel et al. (2004). Experimental sleep curtailment, leptin, ghrelin and appetite in young men.](https://pubmed.ncbi.nlm.nih.gov/15583226/)
- [Rosenstock et al. (2010). INCB13739 in type 2 diabetes inadequately controlled by metformin.](https://pubmed.ncbi.nlm.nih.gov/20413513/)
- [Hintzpeter et al. (2014). Green tea and EGCG inhibition of human 11β-HSD1.](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084468)
- [Hu et al. (2013). Curcumin inhibition of 11β-HSD1 and metabolic measurements in high-fat-fed rats.](https://pubmed.ncbi.nlm.nih.gov/23533564/)
- [Tagawa et al. (2013). Resveratrol inhibition of 11β-HSD1 in rat adipose microsomes.](https://pubmed.ncbi.nlm.nih.gov/23814014/)
- [Tagawa et al. (2014). Erratum to resveratrol inhibition of 11β-HSD1 in rat adipose microsomes.](https://doi.org/10.1530/JOE-13-0066e)
- [Stewart et al. (1987). Mineralocorticoid activity of liquorice and altered cortisol metabolism.](https://pubmed.ncbi.nlm.nih.gov/2889032/)
- [Af Geijerstam et al. (2024). Licorice, renin, aldosterone and home blood pressure: randomized crossover trial.](https://pubmed.ncbi.nlm.nih.gov/38246526/)
- [Chandrasekhar et al. (2012). Ashwagandha root extract in adults with chronic stress.](https://pubmed.ncbi.nlm.nih.gov/23439798/)
- [Hellhammer et al. (2004). Phosphatidic acid/phosphatidylserine complex and mental stress responses.](https://pubmed.ncbi.nlm.nih.gov/15512856/)
- [Sutton et al. (2018). Early time-restricted feeding in men with prediabetes without weight loss.](https://pmc.ncbi.nlm.nih.gov/articles/PMC5990470/)
- [EFSA (2018). Scientific opinion on the safety of green tea catechins.](https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5239)
- [NCCIH. Ashwagandha: usefulness, safety and interactions.](https://www.nccih.nih.gov/health/ashwagandha)
- [Endocrine Society (2008). Diagnosis of Cushing’s syndrome: clinical practice guideline.](https://www.endocrine.org/clinical-practice-guidelines/diagnosis-of-cushing-syndrome)